financetom
Business
financetom
/
Business
/
Anti-ESG backlash in US is overstated, JPMorgan exec says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Anti-ESG backlash in US is overstated, JPMorgan exec says
Oct 2, 2024 10:34 PM

LONDON (Reuters) - The impact of a political backlash against environmental, social and governance-related (ESG) issues in the United States is overstated and having little bearing on the country's burgeoning green economy, a JPMorgan ( JPM ) executive said on Tuesday.

While some companies and investors were saying less about sustainability, they were still moving money in a similar way to peers in Europe, Chuka Umunna, JPMorgan's ( JPM ) global head of sustainable solutions, told the Reuters Energy Transition conference in London.

"If you peel away all the noise and look at what investors are doing, it isn't so different, albeit they may not be using the labels quite in the way that we do in Europe," Umunna, who is also the bank's regional head of green economy investment banking, said.

"The U.S. is not so much pulling back because of the weaponisation of the term ESG, the reality in the States is more complex than that."

A host of U.S.-based investors, including the fund arm of JPMorgan ( JPM ), have pulled back from global climate coalitions this year amid a tense political backdrop as some U.S. Republican politicians said membership could breach antitrust rules.

Despite that, Umunna noted while more anti-ESG resolutions were proposed during the most recent proxy-voting season, less than 2% actually passed. At the state level, meanwhile, less than 10% of anti-ESG bills actually passed.

While those funds trying to raise investment dollars in Republican states might tailor their pitch accordingly, the large global clients of the bank's fund arm tended to stick to a single investment stewardship policy across the globe.

For companies in the real economy of the United States seeking investment or bank loan support, arguably the greater challenges came from inflation, supply-chain issues and high interest rates, he added.

"Is all the noise depressing the valuations? I'm not sure it necessarily is," he said. "I think there are more fundamental issues at play."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Snoop Dogg helps Publicis claim world's largest ad group title
Snoop Dogg helps Publicis claim world's largest ad group title
Dec 4, 2024
LONDON (Reuters) - France's Publicis has enlisted Snoop Dogg, the American rapper who became a breakout star at the Paris Olympics, to help it celebrate overtaking British rival WPP ( WPP ) as the world's largest ad group in 2024. Snoop Dogg was seen everywhere at the Olympics, from carrying the torch to dressing in riding gear at equestrian events...
Update: Market Chatter: TPG Exploring Sale of Crunch Fitness for Over $1.5 Billion
Update: Market Chatter: TPG Exploring Sale of Crunch Fitness for Over $1.5 Billion
Dec 4, 2024
08:07 AM EST, 12/04/2024 (MT Newswires) -- (Update with TPG's response to a request for comment.) TPG Inc ( TPG ) is considering a possible sale of Crunch Fitness that could value the gym chain at over $1.5 billion, including debt, Reuters reported Tuesday citing people familiar with the matter. TPG is working with Jefferies on a sale process that...
Theratechnologies to Commercialize Two RNA-targeted Medicines in Canada
Theratechnologies to Commercialize Two RNA-targeted Medicines in Canada
Dec 4, 2024
08:08 AM EST, 12/04/2024 (MT Newswires) -- Theratechnologies ( THTX ) on Wednesday said it has licensed two investigational RNA-targeted medicines developed by Ionis Pharmaceuticals. Under the agreement, Theratechnologies ( THTX ) receives exclusive rights in Canada for olezarsen, which is being evaluated for familial chylomicronemia syndrome, and severe hypertriglyceridemia, and for donidalorsen, which is being evaluated for the treatment...
Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome
Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome
Dec 4, 2024
08:11 AM EST, 12/04/2024 (MT Newswires) -- Stoke Therapeutics ( STOK ) said Wednesday it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for zorevunersen as treatment for Dravet syndrome with a confirmed mutation in the SCN1A gene. Phase 1/2a and open-label extension studies of zorevunersen showed substantial and sustained reductions in seizure frequency and improvements...
Copyright 2023-2026 - www.financetom.com All Rights Reserved